CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 57 enrolled
Drug / intervention
Sirolimus +6 moredrug
Likely dose
Filgrastim 16 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03077542
NCT03077542Phase 2Active

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Mar 13, 2017·Updated Apr 23, 2026

In Brief

A Phase 2 clinical trial evaluating haploidentical stem cell transplant, Sirolimus, and 5 other interventions for Sickle Cell Disease. Active but no longer recruiting, targeting 57 participants across 1 site.

Detailed Summary

Background: Peripheral blood stem cell transplantation procedures are used for people with sickle cell disease. Researchers want to improve the success and reduce the complications for these procedures. This might allow more people to have a transplant. Objective: To see if a new transplant regime is effective, safe and well tolerated in people with sickle cell disease. Eligibility: Adults at least 18 years old with sickle cell disease and certain complications. A relative who is a half tissue match. Design: Participants will be screened with medical history, physical exam, and blood tests. Recipients will also have: * Heart, lung, and mental health tests * Chest x-rays * Bone marrow taken from the pelvic bone * Eyes and teeth checked Recipients will have a large central line inserted into a vein for up to 6 months. Donors will have their veins tested and have an IV inserted for 1 day or on rare occasions 2 days. Donors will get a drug to activate bone marrow. It will be injected for about 6 days. Donors will have at least 1 five-hour procedure where bone marrow stem cells will be collected. Blood will be taken from a vein in one arm or in rare cases from a groin vein and put through a machine. Some blood will be saved and the rest will be returned. Stem cells will be taken from the saved blood in a lab and frozen until ready to give to the recipient. Recipients will have: * Stems cells collected and frozen * Hygiene lessons * Bone density scans * Low-dose radiation * Drugs for their immune system * Donor cells infused through their central line * Transfusions After about 30 days, recipients will leave the hospital. They must stay near NIH for 3 months after the transplant and have frequent visits. After returning home, they will have 8 visits over 5 years, then be contacted yearly.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
2017201820192020202120222023202420252026
First PostedMar 13, 2017
Enrollment StartApr 6, 2017
Primary CompletionJul 27, 2023
Study CompletionAug 31, 2026
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 9.3 years ago

Interventions

haploidentical stem cell transplantprocedure

haploidentical stem cell transplant

Sirolimusdrug

conditioning regimen

Alemtuzumabdrug

conditioning regimen

Pentostatindrug

conditioning regimen

Cyclophosphamidedrug

conditioning regimen

Hydroxyureadrug

conditioning regimen

Filgrastimdrug

A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).